Research programme: TNF alpha release inhibitors - Renovis
Latest Information Update: 25 Apr 2007
At a glance
- Originator Renovis
- Class Small molecules
- Mechanism of Action Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 25 Apr 2007 Discontinued - Preclinical for Neurological disorders in USA (unspecified route)
- 01 Jun 2004 Preclinical trials in Neurological disorders in USA (unspecified route)